Navigation Links
Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas
Date:12/14/2009

y due to busy schedules, social gatherings, and the pain associated with over activity. However, for many women living with RA this isolation and pain is a common feeling," said Dr. Vibeke Strand, Adjunct Clinical Professor, Division of Immunology/Rheumatology of Stanford University School of Medicine. "More often, many prefer to hide their degree of pain and discomfort from family and friends to avoid hindering the festive celebrations which can lead to a feeling of isolation."

Daily pain is an issue - 63% of respondents live with pain - this can be exacerbated by the dexterity needed for even the simplest of Christmas tasks which is illuminated by the survey with 28% of moderate to severe RA respondents always experiencing pain, find it more difficult or have stopped writing cards altogether.

Shopping for gifts, preparing food, writing cards and wrapping presents are the four festive activities that women living with RA find most difficult to do. Among these women, 28% experience pain and difficulty when shopping for gifts, or have stopped altogether, and more than a quarter report it painful to prepare festive food.

"Nearly two thirds of women living with RA experience pain every day which can be more intense during busy times of the year, such as Christmas and this can seriously impact a patient's enjoyment of the festive season. Almost half of patients included in the survey are not talking to their physician about pain control options which is imperative to enable them to take control of their pain, especially around Christmas when pain can be a considerable issue. This will ensure that more patients achieve a pain free 'good day' and ultimately improve their quality of life." Said Professor Paul Emery, Professor of Rheumatology, University of Leeds.

In light of these survey findings UCB has developed the "12 Tips of Christmas" with tips on how to manage and enjoy the hectic holiday sea
'/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
2. New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
3. UCBs Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis
4. New Survey Shows Devastating Impact of Rheumatoid Arthritis Pain on Intimate Relations
5. Video: New Way RA(TM) Talk Show Premieres Online for People Living With Rheumatoid Arthritis (RA)
6. New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives
7. Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
8. Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models
9. Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis
10. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
11. Use of Biologic Agents Continues to Expand Among US Rheumatologists - Can New Agents Shift the Treatment Paradigm in Rheumatoid Arthritis?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, ... as Sales & Marketing Director. , With more than 25 years of ... for reinforcing Tronics’ business development activities worldwide. He brings to the company his ...
(Date:7/30/2015)... , July 30, 2015 According ... Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity ... Development, Preclinical, Clinical Trial), by End Users - Global ... is expected to reach USD 2,107.99 million by 2020 ... of 15.29%. Browse more than ...
(Date:7/30/2015)... July 30, 2015   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... announced that its strategic partner VetStem Biopharma, Inc. ... study of AT-016, an adipose-derived allogeneic stem cell ... of osteoarthritis pain in dogs. The ...
(Date:7/30/2015)... customers across the globe, ISN improves the efficiency and effectiveness of contractor management systems. ... and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Headquartered in Dallas, TX , ISN has additional offices in ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3
... Therapeutics Inc.,(Lorus), a biopharmaceutical company specializing in the research ... cancer, today reported financial results for the three and ... amounts are in Canadian,dollars., 2008 HIGHLIGHTS, ... Lorus, lead anticancer small ...
... N.J., July 21 Schering-Plough,Corporation (NYSE: SGP ... call and,webcast to review the sales and earnings ... p.m. (EDT) from 8 a.m. today. The quarterly,financial ... after the close of,the New York Stock Exchange., ...
... Limited (TSX: GEN),a company focused on developing ... diseases and personalized health management, today announced,the ... molecular test,for colorectal cancer screening. ColonSentry(TM) is ... risk of having colorectal cancer, identifying,those in ...
Cached Biology Technology:Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 2Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 3Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 4Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 5Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 6Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 7Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 8Schering-Plough Reschedules Time of Conference Call, Webcast for 2008 Second Quarter Earnings to Later Today 2GeneNews launches world's first blood test for colorectal cancer screening 2GeneNews launches world's first blood test for colorectal cancer screening 3
(Date:7/8/2015)... Summary Pancreatic cancer is the 12th ... with a mortality rate of 10.9 deaths per 100,000 ... patients has highlighted a significant need for new and ... by the current market. A highly active pancreatic ... molecule types and mechanisms of action, which provides a ...
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
(Date:7/7/2015)... Research and Markets ... the "Capacitive Fingerprint Sensors Patent Landscape" ... date, fingerprint sensing technology is the most reliable ... well developed. This patent landscape focuses on fingerprint ... domain of capacitive fingerprint sensors is closely linked ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... March 4, 2009 The incidence of pneumothorax (PTX), or ... trauma has been reported to range from 13 50 ... In people, PTX is reported to be the most ... Thoracic ultrasound has been infrequently used as a non-invasive, point-of-care ...
... not lower, costs and very large reductions in greenhouse ... the key take-home messages from a series of expert ... Future (RBAEF)" in a special issue of Biofuels, ... that the collection, which includes a comparative analysis of ...
... March 3, 2009 "Undesirable" evolution in fish ... dwindle -- can actually be reversed in a few ... fishing, according to groundbreaking new research published today by ... Royal Society B . Intensive harvesting of the ...
Cached Biology News:Novel veterinary procedure detecting life-threatening injuries touted 2Cellulosic biofuel technology will generate low-cost green fuel, says major study 2Cellulosic biofuel technology will generate low-cost green fuel, says major study 3'Undesirable' evolution can be reversed in fish, Stony Brook University scientists show 2'Undesirable' evolution can be reversed in fish, Stony Brook University scientists show 3
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Chicken polyclonal to HADHSC - Azide free ( Abpromise for all tested applications). Antigen: Amino acids 57-314 of HADHSC Entrez GeneID: 3033 Swiss Protein ID: Q16836...
Biology Products: